Our brain tumor team is currently enrolling patients with recurrent brain tumors for a new Phase I clinical trial that harnesses CAR T immunotherapy to fight advanced brain cancers.
- Patients: If you are a patient interested in learning more about our clinical trials, please email [email protected] or call 833-310-CART (2278).
- Physicians: If you are a physician and wish to refer a patient for enrollment, please email us at [email protected] or call 833-310-CART (2278).
- News media: Contact us by email at [email protected] or call 626-218-8803.
You can learn more about this clinical trial online at ClinicalTrials.gov.
IRB #13384: Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma
In this ‘first in human’ clinical study, we are evaluating the safety and feasibility of reprogramming a patient’s own immune system to target malignant glioma. For this study, white blood cells known as T cells are isolated and engineered to express a protein of novel design called a chimeric antigen receptor (CAR). This CAR instructs the T cells to recognize and kill target cells that express IL13Rα2, a receptor readily detected on the majority of malignant gliomas, but not on normal brain tissue.
Research participants will be enrolled on one of two treatment arms based on surgical need: 1) tumor resection or 2) tumor biopsy for non-resectable tumors. At the time of surgery, a catheter system will be placed for local delivery of the reprogrammed T cells at the tumor site. Following recovery from surgery and cell manufacture, research participants will receive weekly injections of the CAR T cells for 3 weeks, with an option for an additional 3-week treatment course.
Patient Eligibility Requirements:
- Patient has had a prior, histologically-confirmed diagnosis of a grade III or grade IV glioma.
- Radiographic evidence of progression/recurrence of the measurable disease more than 12 weeks after the end of radiation therapy.
- COH clinical pathology to confirm IL13Rα2+ tumor expression by immunohistochemistry.
- Karnofsky Performance Score ≥60%.
- Male or female research participants between 18-75 years of age.
If you are interested in learning more about this clinical trial or in referring a patient for enrollment, please call 833-310-CART (2278) or email [email protected]. For a summary of this study including the full eligibility criteria, visit City of Hope’s clinical trials website at http://clinicaltrials.coh.org and enter “13384” in the keyword search.